Skip to main content

Table 3 Patients with a change in PROs greater than the MIC from baseline to 24 months

From: Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study

PRO

Exenatide BID

Insulin

(N = 873)*

(N = 1025)*

EQ-5D index score

n = 739

n = 893

 n (%) improving by > MIC (0.03)

279 (32.0)

280 (27.3)

 n (%) worsening by > MIC (0.03)

194 (22.2)

288 (28.1)

EQ-5D VAS score

n = 716

n = 868

 n (%) improving by > MIC (3.0)

414 (47.4)

458 (44.7)

 n (%) worsening by > MIC (3.0)

150 (17.2)

224 (21.9)

DHP-18 (standardised scores)

  

Barriers to activity

n = 736

n = 896

 n (%) improving by > MIC (5.29)

231 (26.5)

251 (24.5)

 n (%) worsening by > MIC (5.29)

174 (19.9)

250 (24.4)

Disinhibited eating

n = 741

n = 899

 n (%) improving by > MIC (2.80)

364 (41.7)

415 (40.5)

 n (%) worsening by > MIC (2.80)

247 (28.3)

308 (30.0)

Psychological distress

n = 731

n = 890

 n (%) improving by > MIC (4.87)

306 (35.1)

365 (35.6)

 n (%) worsening by > MIC (4.87)

254 (29.1)

311 (30.3)

  1. PRO = patient-reported outcome; MIC, minimally important change; BID = twice daily, EQ-5D = EuroQoL-5D, VAS = visual analogue scale, DHP-18 = Diabetes Health Profile-18.
  2. *N numbers represent the number of patients who attended a 24-month visit. Percentages are based on N. The number of patients with data for each endpoint (n) is presented above each endpoint.
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us